Dan Crowley is co-founder and CEO of RemedyBio, and is focused on strategic leadership of the company, supporting our great team, and building transformational partnerships with industry leaders. Prior to RemedyBio, Dan co-founded and led Genomics Medicine Ireland (acquired in 2018) and was a Venture Partner with ARCH Venture Partners.

He serves on the board of the AMBER Centre for Advanced Materials and Bioengineering Research headquartered at Trinity College Dublin. Dan holds a BA and MSc from Trinity College Dublin, a PDip from Oxford University, received his MBA from Cornell where he was an Angear Merit Scholar, and is a Kauffman Fellow.

Dr. Leach is an executive leader, scientist and entrepreneur. Through his career, he has built domain expertise in human genomics, big data, A.I., reproductive medicine, aerospace, manufacturing, corporate strategy and business development. Demonstrating the ability to lead from concept through delivery, Dr. Leach has led fundamental technologies to successful business endpoints by creating effective company architecture, market development, and global commercialization. Some of his previous roles include Chief Strategy Officer at the International Space Station US National Laboratory, Chief Strategy Officer at Sequence Bio, Chief Commercial Officer at WuXi NextCode Genomics, Vice President at Complete Genomics, Vice resident at deCODE Genetics, and Chief Science Officer and Founder at Teneo Sciences. While at those companies, Dr. Leach created the business strategies and successfully led the implementation of various technologies for research and clinical diagnostic applications in multiple geopolitical environments. With significant involvement in population-specific and nation-scale discovery biology programs, he has led successful business opportunities in 28 countries around the world. In addition to this, he has gained high-level governance experience during service on several Boards of Directors.

Dr. Leach holds a B.S. degree in Biology from Hillsdale College, a Ph.D. in Molecular Biology from Ohio University, was a Fellow in the Division of Experimental Therapeutics at Walter Reed Army Institute of Research for the US Department of Defense and was a Visiting Fellow at the National Cancer Institute of the National Institutes of Health.

Paul Leonard is co-founder and CSO of RemedyBio, and is focused on the scientific leadership of the company. Paul is the lead inventor of Remedy technology and related patents and is supported by a diverse technical team within the company. Paul is a former Ass. Prof. of Biomedical Sciences at Dublin City University and prior to RemedyBio has held senior management roles at the cancer biotech companies Vaccinogen Inc. and WntResearch AB.

Paul holds a B.Sc. in Biotechnology and a Ph.D in Applied Immunology from Dublin City University and is a certified Lean Six Sigma Green Belt.

Colm Galligan is Chief Medical Officer of RemedyBIo, and is focussed on translating our technology’s potential into patient-centred outcomes. His experience as medical doctor, a pharmaceutical industry Medical Director and a patient advocate ideally places him to form innovative collaborations across scientific, clinical, patients & industry leaders.

Colm holds medical and MSc degrees from Trinity, as well as an MBA from UCD’s Smurfit Business School. He is a Fellow of the Faculty of Pharmaceutical Medicine (RCP UK). Colm is an active member of PKU Ireland and a former IPPOSI board member.

Ashley is a seasoned biopharma executive and has spent his career on the business side of science. He has worked with small and large companies, identifying and closing product and technology deals, managing contracts and alliances, and creating and growing new businesses. Prior to Remedy, he was part of the executive team at Domain Therapeutics focusing on licensing and alliances with Pharma and biotech companies, and creating asset centric companies around early stage projects.

Isabel Vega-Carrascal has decades of international R&D and leadership experience in the Biotechnology and MedTech industries. She has held positions in R&D and Operations management in Germany, Belgium, UK, Denmark, Japan, Italy and Ireland prior to joining Remedy Bio.

Isabel holds a PhD in Diagnostics and Therapeutics from the Royal College of Surgeons in Ireland, a B.A. (Mod) in Biochemistry from Trinity College Dublin and studied Chemical Engineering at the University of Valladolid in Spain.

Dr. Christopher Miller is a pharmaceutical R&D leader with 25 years of experience in genomics and genetics-driven target and drug discovery. He has held leadership roles in various pharmaceutical companies, including Genetic Institute, Wyeth (pre-Pfizer acquisition), Bristol Myers Squibb, AbbVie, and GlaxoSmithKline. At GSK, he served as Vice President and Global Head of Functional Genomics, where he led his teams in delivering high-quality omics and multi-omics data sets and advancing numerous targets into Disease Area pipelines.

Dr. Miller has also collaborated significantly with leading academic research teams and is recognized as an effective thought-leader and champion for genomics and genetics-driven target and drug discovery. He has a deep knowledge of exploratory biology, target hunting, target validation, and translational research in multiple disease areas. He has worked extensively in developing and applying technologies to assess gene and protein function in highly translational model systems.

Dr. Miller holds a Ph.D. in Pharmacology from Michigan State University and completed post-doctoral training in Molecular Endocrinology at the Massachusetts General Hospital in Boston. He has recently joined RemedyBio's Scientific Advisory Board, where his expertise in target and discovery will be critical in helping the company choose new effective precision therapies for the treatment of cancer.

Dr. Papa is chief medical officer at Enara Bio. Previously, she was a consultant medical oncologist at King’s College London (KCL) and Guy’s and St Thomas’ NHS Foundation Trust (GSTFT), where she remains a clinical reader in immuno-oncology. Sophie has extensive clinical trial experience as a principal investigator in the GSTFT early phase trials team, with a particular focus on the design and delivery of first-in-human studies of T-cell therapies for solid tumours. Sophie completed her medical training at the University of Oxford and Imperial College London, and went on to complete a PhD in solid tumour CAR T-cell cancer immunotherapy at King’s College London.

Prof. O’Neill holds the Chair of Biochemistry at Trinity College Dublin where he leads the Inflammation Research Group. After receiving his PhD in pharmacology from the University of London, he carried out postdoctoral research at the Strangeways Research Laboratory in Cambridge, funded by the Medical Research Council. His research is focused on the molecular basis of inflammation, with a particular emphasis on innate immunity, toll-like receptors, inflammasomes and metabolic reprogramming in macrophage activation. O’Neill has been named by Clarivate/Thomson Reuters as one of the world’s most influential scientists and has won numerous awards for his research. These include the European Federation of Immunology Societies medal, the International Cytokine and Interferon Society Milstein Award, The Royal Dublin Society Boyle Medal for Scientific Excellence and The Royal Irish Academy Gold Medal for Life Sciences. He was elected a Fellow of the Royal Society in 2016.

Dr. Chowdhury is a consultant medical oncologist and is actively involved in clinical trial research. He received his first degree from the University of Cambridge and qualified as a doctor at Guy’s and St Thomas’ Medical School.